MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping

Area of Science:

• Oncology
• Genetics
• Bioinformatics

Background:

• Precision oncology relies on comprehensive genetic profiling using next-generation sequencing (NGS).
• Accurate variant annotation is crucial for translating DNA alterations into actionable protein-level predictions.
• The MET gene is frequently implicated in various cancers, with specific mutations conferring therapeutic resistance.

Purpose of the Study:

• To highlight inconsistencies in variant annotation for MET resistance mutations, specifically focusing on exon 19 alterations.
• To demonstrate how the same resistance mutation can be annotated differently based on transcript variations.
• To emphasize the critical need for standardized and accurate variant annotation in precision oncology.

Main Methods:

• Analysis of genetic variant data from next-generation sequencing.
• Comparison of variant annotations across different MET gene transcripts.
• Identification and exemplification of annotation discrepancies for MET D1228N and D1246N mutations.

Main Results:

• Identified inconsistencies in the annotation of MET D1228N and D1246N resistance mutations.
• Demonstrated that these represent the same resistance mutation within MET exon 14 skipping alterations but are annotated on different transcripts.
• Provided additional examples of variants with similar annotation issues across different transcripts.

Conclusions:

• Inconsistent variant annotation poses a significant risk of erroneous interpretation in precision oncology.
• Standardization of annotation practices is essential to ensure the reliable application of genetic profiling in cancer treatment.
• Addressing these annotation discrepancies is vital for the effective implementation of precision medicine strategies.